Key result
In a canine model of ischemia and reperfusion, BAY-U3405 reduced infarct size by 65% and suppressed reperfusion arrhythmias compared to placebo.
Why the study?
Does BAY-U3405 reduce infarct size and reperfusion arrhythmias in a canine model of ischemia and reperfusion?
Does BAY-U3405 reduce infarct size and reperfusion arrhythmias in a canine model of ischemia and reperfusion?
The thromboxane antagonist BAY-U3405 significantly reduced infarct size and reperfusion arrhythmias in a canine model of myocardial ischemia-reperfusion.
Answers are grounded in this paper and cite their sources.
May warrant human trials of thromboxane antagonism in MI; leaves open clinical translation from canine data.
The effects of a novel thromboxane antagonist, (3R)-3-(4-fluorophenylsulfonmido)-1,2,3,4-tetrahydro-9-carbazol epropanoic acid (BAY-U3405), on myocardial damage due to ischemia and reperfusion (added to accelerate the initiated injury) were studied in anesthetized dogs. The left anterior descending (LAD) coronary artery was occluded for 6 hours and reperfused for 30 minutes. BAY-U3405, 1 mg/kg, was injected intravenously 15 minutes after LAD occlusion, followed by continuous infusion of 10 mg/kg/hour starting at 30 minutes after occlusion. The drug had no hemodynamic effects. During the experiments 6 of 14 animals died of ventricular fibrillation (VF) in the placebo-vehicle controls (3 during occlusion and 3 during reperfusion); in the drug-treated group 5 of 13 dogs died of VF (all during occlusion none during reperfusion). This difference in total mortality and cause was not statistically significant. Reperfusion arrhythmias were largely suppressed by BAY-U3405: 201 +/- 43 versus 689 +/- 98 irregular beats during 30 minutes (p less than 0.001) in the experimental and control groups, respectively. Coronary collateral flow, obtained from a load-line analysis by measurement of retrograde coronary flow, and collateral index were similar in both groups. Therefore, BAY-U3405 did not alter collateral blood supply to the ischemic myocardium. Infarct size, determined with tetrazolium staining, was reduced by 65% (p less than 0.01) after its administration. These results suggest that thromboxane antagonism by BAY-U3405 may delay infarct expansion and reduce the frequency of ventricular arrhythmias during reperfusion of previously ischemic myocardium.
No takes yet. Share an insight, caveat, or question.
Fiedler et al. (1991) studied Myocardial damage due to ischemia and reperfusion (n=27). BAY-U3405 vs. Placebo-vehicle was evaluated on Infarct size (65% reduction, p=<0.01). In a canine model of ischemia and reperfusion, BAY-U3405 reduced infarct size by 65% and suppressed reperfusion arrhythmias compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: